EUVIMEDEUVIMED entdecken
Crossref

In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa

Feng Yang, Yang Yang, Shi Wu, Chengkang Tang, Dandan Yin, Yan Guo, Demei Zhu, Fupin Hu

European Journal of Clinical Microbiology & Infectious Diseases · 2025-11 · 44 (11) · 2705-2715

DOI: 10.1007/s10096-025-05232-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 12.08.2025. Verfasst von Feng Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China. Hauptthemen laut MEDLINE: Meropenem, Pseudomonas aeruginosa, beta-Lactamase Inhibitors, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission, Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai, China Antimicrobial Surveillance Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Carbapenem-resistant organisms pose a significant public health threat due to high mortality and limited treatment options. This study aimed to evaluate the in vitro antimicrobial activity of the novel β-lactamase inhibitor FL058 combined with meropenem against carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa clinical isolates. METHODS: The MICs of 85 clinical isolates, including KPC- or NDM-producing Enterobacterales and carbapenem-resistant/susceptible P. aeruginosa, were determined using broth microdilution. Additionally, bactericidal activity, effects of culture conditions, post-antibiotic effect, and post-β-lactamase inhibitory effect of meropenem-FL058 were evaluated. Ceftazidime-avibactam served as comparator. RESULTS: Meropenem-FL058 showed potent activity against KPC-producing Enterobacterales (100% susceptibility, MIC90 ≤ 0.25 mg/L, most MBC90/MIC90 ratios = 1) and moderate activity against NDM-producing Enterobacterales (> 58% susceptibility, MIC90 ≤ 0.06 mg/L for E. coli, 8 mg/L for Klebsiella pneumoniae, and 64 mg/L for other carbapenem-resistant Enterobacterales, most MBC90/MIC90 ratios = 2). Of note, NDM-producing E. coli achieved a susceptibility of 91.7%. Meropenem-FL058 showed susceptibility rates of 73.9% for NDM-1 and 62.5% for NDM-5-producing strains. Activity against carbapenem-resistant P. aeruginosa was limited (18.2% susceptibility, MIC90 = 16 mg/L, MBC90/MIC90 ratio = 8). Inoculum density and culture medium pH significantly affected the antimicrobial activity, while serum and metal ions had minimal effects. No significant post-antibiotic effect or post-β-lactamase inhibitory effect was observed. CONCLUSION: Meropenem-FL058 showed promising in vitro activity against KPC-producing Enterobacterales and some NDM-1/5-producing strains. However, its limited efficacy against certain NDM-producers and carbapenem-resistant P. aeruginosa highlights the variability in activity across different resistance mechanisms, suggesting the potential need for combination strategies in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemPseudomonas aeruginosabeta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesEnterobacteriaceaeMicrobial Sensitivity TestsHumansEnterobacteriaceae InfectionsPseudomonas InfectionsCarbapenem-Resistant Enterobacteriaceae

Stichwörter der Autor:innen

Pseudomonas aeruginosaAntimicrobial susceptibility testingEnterobacteralesFL058Meropenem

Substanzen

Meropenembeta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-Lactamasesbeta-lactamase NDM-1

Autor:innen und Institutionen

  • Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China.
  • Department of Laboratory Medicine, Huadong Hospital, Fudan University, Shanghai, 200040, China.
  • Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-resistant Bacterial Infections and Innovative Drug R&D, Huashan Hospital, Shanghai, 201112, China.
  • Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, 200040, China.
  • Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China. guoyan@fudan.edu.cn.
  • Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, 200040, China. guoyan@fudan.edu.cn.

Förderung

  • Shanghai Municipal Health Commission
  • Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai
  • China Antimicrobial Surveillance Network
  • Shanghai Antimicrobial Surveillance Network

Zitieren

APA

Yang, F., Yang, Y., Wu, S., Tang, C., Yin, D., Guo, Y., Zhu, D., & Hu, F. (2025). In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa. European Journal of Clinical Microbiology & Infectious Diseases, 44(11), 2705-2715. https://doi.org/10.1007/s10096-025-05232-3

Vancouver

Yang F, Yang Y, Wu S, Tang C, Yin D, Guo Y, et al. In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa. European Journal of Clinical Microbiology & Infectious Diseases. 2025;44(11):2705-2715. doi:10.1007/s10096-025-05232-3

BibTeX
@article{Yang2025,
  author = {Yang, Feng and Yang, Yang and Wu, Shi and Tang, Chengkang and Yin, Dandan and Guo, Yan and Zhu, Demei and Hu, Fupin},
  title = {In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2025},
  volume = {44},
  number = {11},
  pages = {2705--2715},
  doi = {10.1007/s10096-025-05232-3}
}
Kostenlos starten →